- Actavis to pare down sales staff of branded-drugs division
- GPhA: FDA’s proposed rule on prescription drug labeling adds $4 billion to healthcare costs
- 21 health industry groups address FDA on proposed changes to generic drug label rules
- Generic drug prices spike, but PBMs' reimbursement rates don't keep up, NCPA study finds
- Actavis applies for approval of generic version of Absorica
PARSIPPANY, N.J. — Actavis is looking into the possibility of buying Warner Chilcott, the generic drug maker said Friday.
Actavis, the world's third-largest generic drug maker, said it had entered into early-stage discussions with Warner Chilcott about a potential combination of the two, but that no agreement had been reached, and that it wouldn't issue further comment about the matter.
Last month, according to published reports, a proposal by Canadian drug maker Valeant Pharmaceuticals International to acquire Actavis fell through. Valeant had been planning to pay more than $13 billion in stock to acquire the generic drug maker, but the two could not agree to terms of the deal.
Actavis reported sales of $5.91 billion in its fiscal year 2012 earnings, while Warner Chilcott had sales of $2.475 billion.